Year: 2025
Type: article
Abstract: Objective: To explore the efficacy of combination therapy of tyrosine kinase inhibitor (TKIs) and immune checkpoint inhibitor (ICIs) in patients with anaplastic thyroid carcinoma (ATC). Method: This study enrolled 7 patients with ATC between June 2020 and June 2024, and conducted follow-up for a minimum of 6 months post-treatment, with the longest follow-up duration reaching 4 years. Patients received treatment with the TKI-Anlotinib and the ICI-Sintilimab, administered every 3 weeks in a treatment cycle. Result: Following treatment, among the 7 patients, the primary lesion in 3 patients who had not undergone thyroidectomy exhibited significant shrinkage, the lung metastases in 5 patients with pulmonary involvement significantly regressed, and the lateral cervical lymph node metastases in all patients demonstrated notable reduction. Conclusion: Combination therapy of TKIs and ICIs for the treatment of ATC patients can be highly effective and bringing better therapeutic outcomes and quality of life for patients.
Source: Frontiers in Oncology
Authors: Xi Zhang, Hongzhi Lu, Yuanshi Lv, Hong Gao, Hui Jin
Institution: Jilin Province Tumor Hospital
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W4410617353